Primary Biliary Cholangitis

AASLD develops evidence-based practice guidelines and practice guidances which are updated regularly by a multi-disciplinary panel of experts, including hepatologists, and include recommendations of preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. 

Practice Guidance 

Primary Biliary Cholangitis (PBC) is considered an autoimmune disease because of its hallmark serologic signature, antimitochondrial antibody (AMA), and specific bile duct pathology. The etiology of PBC is thought to be due to a combination of genetic risk factors and environmental triggers.

Guidance on Primary Biliary Cholangitis [updated November 2018]

The AASLD 2021 Practice Guidance on Primary Biliary Cholangitis (PBC) is a focused update of the PBC guidance published in 2018. The major changes from the last guidance to this guidance include information about obeticholic acid (OCA).

Primary Biliary Cholangitis: 2021 Practice Guidance Update